menu
    • menu
    [{"orgOrder":0,"company":"Virchow Group","sponsor":"Adocia","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"INDIA","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Biochaperone Pdgf-Bb","moa":"PDGF","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Virchow Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Virchow Group \/ Adocia","highestDevelopmentStatusID":"7","companyTruncated":"Virchow Group \/ Adocia"},{"orgOrder":0,"company":"Virchow Group","sponsor":"Adocia","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"FRANCE","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Biochaperone Pdgf-Bb","moa":"PDGF","graph1":"Podiatry","graph2":"Phase III","graph3":"Virchow Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virchow Group \/ Virchow Group","highestDevelopmentStatusID":"10","companyTruncated":"Virchow Group \/ Virchow Group"},{"orgOrder":0,"company":"Virchow Group","sponsor":"The Russian Direct Investment Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Virchow Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virchow Group \/ The Russian Direct Investment Fund","highestDevelopmentStatusID":"15","companyTruncated":"Virchow Group \/ The Russian Direct Investment Fund"},{"orgOrder":0,"company":"Virchow Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Virchow Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virchow Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Virchow Group \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Virchow Group

    Menu

    Virchow Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Virchow Group

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Virchow Group

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients

                            Details : V-Immune (Immunoglobulin) is a Antibody drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Immunologic Deficiency Syndromes.

                            Product Name : V-Immune

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 12, 2025

                            Lead Product(s) : Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Virchow Group

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Virchow Group

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : The Russian Direct Investment Fund

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            RDIF Partners with Virchow Biotech for Production of Sputnik V Vaccine in India

                            Details : Agreement will facilitate the full-scale local production of the Sputnik V vaccine in India and to supply our international partners globally.

                            Product Name : Sputnik V

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 22, 2021

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : The Russian Direct Investment Fund

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Virchow Group

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Virchow Group

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Biochaperone Pdgf-Bb

                            Therapeutic Area : Podiatry

                            Study Phase : Phase III

                            Recipient : Adocia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 3 Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabe...

                            Details : Biochaperone Pdgf-Bb is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 11, 2014

                            Lead Product(s) : Biochaperone Pdgf-Bb

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase III

                            Recipient : Adocia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Virchow Group

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Virchow Group

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Biochaperone Pdgf-Bb

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I/ Phase II

                            Sponsor : Adocia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulc...

                            Details : Biochaperone Pdgf-Bb is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 02, 2010

                            Lead Product(s) : Biochaperone Pdgf-Bb

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Adocia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth